Teacher Retirement System of Texas Boosts Stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL)

Teacher Retirement System of Texas boosted its stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) by 10.0% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 27,777 shares of the biopharmaceutical company’s stock after purchasing an additional 2,526 shares during the period. Teacher Retirement System of Texas’ holdings in Ocular Therapeutix were worth $237,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of OCUL. Charles Schwab Investment Management Inc. grew its stake in shares of Ocular Therapeutix by 146.6% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,110,460 shares of the biopharmaceutical company’s stock valued at $9,661,000 after acquiring an additional 660,080 shares during the period. Patient Square Capital LP purchased a new stake in shares of Ocular Therapeutix in the third quarter worth $2,049,000. Polar Asset Management Partners Inc. purchased a new stake in shares of Ocular Therapeutix in the third quarter worth $4,288,000. FMR LLC raised its position in shares of Ocular Therapeutix by 7,098.7% during the 3rd quarter. FMR LLC now owns 434,369 shares of the biopharmaceutical company’s stock valued at $3,779,000 after purchasing an additional 428,335 shares during the period. Finally, Barclays PLC lifted its stake in shares of Ocular Therapeutix by 37.1% during the 3rd quarter. Barclays PLC now owns 511,522 shares of the biopharmaceutical company’s stock valued at $4,451,000 after buying an additional 138,441 shares in the last quarter. Institutional investors own 59.21% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have commented on the company. Needham & Company LLC started coverage on Ocular Therapeutix in a report on Tuesday, March 11th. They set a “buy” rating and a $15.00 price target on the stock. Royal Bank of Canada assumed coverage on Ocular Therapeutix in a research note on Tuesday, March 18th. They set an “outperform” rating and a $17.00 target price on the stock. JMP Securities set a $19.00 price objective on shares of Ocular Therapeutix in a report on Tuesday, March 4th. Finally, HC Wainwright reissued a “buy” rating and issued a $15.00 target price on shares of Ocular Therapeutix in a report on Tuesday, March 4th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $16.38.

Insider Activity

In related news, insider Pravin Dugel sold 21,475 shares of the company’s stock in a transaction dated Monday, February 24th. The shares were sold at an average price of $6.87, for a total transaction of $147,533.25. Following the transaction, the insider now directly owns 3,520,318 shares in the company, valued at approximately $24,184,584.66. This represents a 0.61 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Donald Notman sold 11,119 shares of the firm’s stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $7.81, for a total value of $86,839.39. Following the sale, the insider now directly owns 193,444 shares of the company’s stock, valued at $1,510,797.64. This represents a 5.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 38,895 shares of company stock valued at $283,772 in the last ninety days. Insiders own 3.50% of the company’s stock.

Ocular Therapeutix Stock Down 10.8 %

Shares of OCUL opened at $6.54 on Wednesday. The company has a debt-to-equity ratio of 0.19, a current ratio of 13.01 and a quick ratio of 12.94. The stock has a market capitalization of $1.04 billion, a price-to-earnings ratio of -4.95 and a beta of 1.34. Ocular Therapeutix, Inc. has a 1 year low of $4.06 and a 1 year high of $11.78. The business’s 50 day simple moving average is $7.48 and its 200-day simple moving average is $8.73.

Ocular Therapeutix (NASDAQ:OCUL) last released its quarterly earnings results on Monday, March 3rd. The biopharmaceutical company reported ($0.29) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.05). Ocular Therapeutix had a negative net margin of 283.74% and a negative return on equity of 45.18%. The business had revenue of $17.08 million for the quarter, compared to analysts’ expectations of $16.89 million. As a group, equities analysts expect that Ocular Therapeutix, Inc. will post -0.98 earnings per share for the current fiscal year.

About Ocular Therapeutix

Ocular Therapeutix, Inc, a biopharmaceutical company, focuses on the formulation, development, and commercialization of therapies for diseases and conditions of the eye using its bioresorbable hydrogel-based formulation technology in the United States. The company markets DEXTENZA, a dexamethasone ophthalmic insert to treat post-surgical ocular inflammation and pain following ophthalmic surgery, as well as allergic conjunctivitis.